No Data
Ranking of volume change rate (10 am slot) - Data SEC, JGB double, etc. are ranked.
In the volume change rate ranking, by comparing the average volume over the last five days with the volume on the distribution day, one can understand the trends in stock selection and the interests of market participants. ■ Top Volume Change Rates [As of November 22, 10:32] (Comparison of the average volume over the last five days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <2251> JGB Double 3381101432.177388.78%0.0002%<9161>
The TOPIX Growth Index slightly rose, temporarily falling into negative territory due to heavy resistance on the upside.
Tokyo Stock Exchange Growth Market Index 809.19 +0.65 / volume 0.1 billion 65.57 million shares / transaction value 93.8 billion yen Tokyo Stock Exchange Growth Market 250 Index 631.50 +0.12 / volume 75.87 million shares / transaction value 73.4 billion yen Today's growth market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index, continue to modestly rise, with 286 gainers, 260 losers, and 42 unchanged. Today's growth market trended with resistance to higher prices. As of the previous day on the 11th.
Volume change rate ranking (9 o'clock) - Micronics, MediaLink, etc. are ranked.
In the volume change rate ranking, you can understand the market participants' interest in trends such as market color by comparing the average volume of the last 5 days and the volume on the delivery day. ■ Top Volume Change Rate [As of 9:32 on November 12th] (Comparison of average volume of the last 5 days) Stock Code Company Name Volume 5-day Average Volume Volume Change Rate Stock Price Change Rate ＜6640＞I・PEX 556700107 185.08 300.42% 0.23 13% ＜6659＞Mede
Stocks hitting the upper or lower price limit in the afternoon session.
■Stock price limit up: <2185> C.I.M. C.I. <3077> Hori Food Service <3807> Fisco <3842> Next Gen <3857> Rack <4320> CE Holdings <4448> Kubell <4475> HENNNGE <4588> Oncorice Bio Pharma <4783> NCD ■Stock price limit down: <269A> Sapeet <2901> Weldish <4071> Plus Alpha Consulting <4634> artien
Oncolys BioPharma Reports Decline in Sales Amidst Uncertainty
Oncolys BioPharma: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
No Data
No Data